a Renal Division , The People's Hospital of Tibet Autonomous Region , Lhasa , China.
b Renal Division , Peking University First Hospital , Beijing , China.
Ren Fail. 2019 Nov;41(1):636-643. doi: 10.1080/0886022X.2019.1635892.
Mineral and bone disorder (MBD) in hemodialysis patients is associated with increased morbidity and mortality. Studies on the MBD status of hemodialysis patients at high altitudes are extremely limited. A total of 146 hemodialysis patients from 5 local hospitals across all districts with hemodialysis centers in the Tibetan Plateau were enrolled in this cross-sectional study. Parameters related to MBD, including serum phosphorus (P), calcium (Ca), and intact parathyroid hormone (iPTH) levels, were measured. The achievement of MBD goals was compared with the achievement in the Dialysis Outcomes and Practice Study (DOPPS) 3, DOPPS 4 and a multicenter study of MBD in China. Factors associated with hyperphosphatemia were examined. Altogether, 146 hemodialysis patients were recruited from the Tibetan Plateau. According to the K/DIGO guidelines, there were low achievement rates for serum Ca (40.4%), P (29.7%), and iPTH (47.1%). As for the (KDOQI) guidelines, the rates of achievement of defined targets were 38.4%, 33.7% and 16.4% for serum Ca, P and iPTH, respectively. The percentages of patients reaching the KDOQI targets for corrected Ca, P, and iPTH were significantly lower for Tibetan patients than the percentages found in DOPPS 3 (38.4% vs. 50.4%, 33.7% vs. 49.8%, and 16.4% vs. 31.4%, respectively, all < .001) and DOPPS 4 (38.4% vs. 56.0%, 33.7% vs. 54.5%, and 16.4% vs. 35.3%, respectively, all < .001). The percentage of patients reaching the KDOQI targets for iPTH was significantly lower in Tibet than in the plain areas of China (16.4% vs. 26.5%, < .001). The proportion of patients with hypocalcemia was higher in Tibet than in the plain areas (44.5% vs. 19.4%, < .001). The percentage of local patients with optimal P was significantly higher for patients with an activated vitamin D prescription than for patients without an activated vitamin D prescription (45.3% vs. 19.3%, < .001). Age and the activated vitamin D prescription were independently associated with hyperphosphatemia. The MBD status of hemodialysis patients in Tibet is far from the ideal level. High altitude is one of the possible causes of the differences found, but not the principal one. It is necessary for medical staff in Tibet to improve the detection and treatment of MBD.
西藏高原地区血液透析患者矿物质和骨代谢紊乱的现状
血液透析患者的矿物质和骨代谢紊乱(MBD)与发病率和死亡率的增加有关。关于高原地区血液透析患者 MBD 状况的研究极为有限。本研究纳入了来自西藏高原地区 5 家医院的 146 名血液透析患者,这些医院均设有血液透析中心。测定了与 MBD 相关的参数,包括血清磷(P)、钙(Ca)和全段甲状旁腺激素(iPTH)水平。将 MBD 目标的达标情况与 Dialysis Outcomes and Practice Study(DOPPS)3、DOPPS 4 和中国 MBD 的多中心研究进行了比较。并对高磷血症的相关因素进行了分析。
总共从西藏高原招募了 146 名血液透析患者。根据 K/DIGO 指南,血清 Ca(40.4%)、P(29.7%)和 iPTH(47.1%)的达标率较低。根据(KDOQI)指南,血清 Ca、P 和 iPTH 的达标率分别为 38.4%、33.7%和 16.4%。藏族患者血清 Ca、P 和 iPTH 达 KDOQI 目标的百分比明显低于 DOPPS 3(38.4% vs. 50.4%,33.7% vs. 49.8%,16.4% vs. 31.4%,均 P<0.001)和 DOPPS 4(38.4% vs. 56.0%,33.7% vs. 54.5%,16.4% vs. 35.3%,均 P<0.001)。藏族患者血清 iPTH 达 KDOQI 目标的百分比明显低于中国平原地区(16.4% vs. 26.5%,P<0.001)。藏族患者低钙血症的比例高于平原地区(44.5% vs. 19.4%,P<0.001)。与未服用活性维生素 D 制剂的患者相比,服用活性维生素 D 制剂的患者血清 P 达标率更高(45.3% vs. 19.3%,P<0.001)。年龄和活性维生素 D 制剂的使用与高磷血症有关。
西藏高原地区血液透析患者的 MBD 状况远未达到理想水平。高原可能是造成差异的原因之一,但不是主要原因。西藏地区的医务人员有必要提高对 MBD 的检测和治疗水平。